We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.
For more information visit our privacy policy.Common Contracts
4 similar Merger Agreement contracts by Five Prime Therapeutics, Inc., Gilead Sciences Inc, Oyster Point Pharma, Inc., Translate Bio, Inc.
AGREEMENT AND PLAN OF MERGERMerger Agreement • November 8th, 2022 • Oyster Point Pharma, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of November 7, 2022 (the “Agreement Date”), by and among Viatris Inc., a Delaware corporation (“Parent”), Iris Purchaser Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and Oyster Point Pharma, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement shall have the meanings ascribed to such terms in Article 1.
Standard Contracts
AGREEMENT AND PLAN OF MERGER among: SANOFI, VECTOR MERGER SUB, INC. and TRANSLATE BIO, INC. Dated as of AUGUST 2, 2021Merger Agreement • August 3rd, 2021 • Translate Bio, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER is made and entered into as of August 2, 2021, by and among: Sanofi, a French société anonyme (“Parent”); Vector Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Purchaser”); and Translate Bio, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER by and among: AMGEN INC., FRANKLIN ACQUISITION SUB, INC., and FIVE PRIME THERAPEUTICS, INC. Dated as of March 4, 2021Merger Agreement • March 4th, 2021 • Five Prime Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of March 4, 2021 (the “Agreement Date”), by and among Amgen Inc., a Delaware corporation (“Parent”), Franklin Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and Five Prime Therapeutics, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement shall have the meanings ascribed to such terms in Article 1.
AGREEMENT AND PLAN OF MERGER among: FORTY SEVEN, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and TORO MERGER SUB, INC., a Delaware corporation Dated as of March 1, 2020 Section 1 THE OFFERMerger Agreement • March 2nd, 2020 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of March 1, 2020, by and among: Gilead Sciences, Inc., a Delaware corporation (“Parent”); Toro Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”); and Forty Seven, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.